|Infinity to Present at 37th Annual Cowen and Company Healthcare Conference|
Feb 27, 2017
|CAMBRIDGE, Mass., Feb. 27, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Cowen and Company 37th Annual Healthcare Conference on Monday, March 6, 2017, at 4:00 p.m. ET in Boston, MA. A live webcast of Infinity's presentation will be accessible on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.
Infinity is an innovative biopharmaceutical company dedicated to a... |
|Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer|
Feb 13, 2017
|CAMBRIDGE, Mass., Feb. 13, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Jeffery Kutok, M.D., Ph.D. has been promoted to the role of chief scientific officer, effective immediately. In this role, Dr. Kutok will be responsible for overseeing biology and translational science efforts, including preclinical collaborations, to support the ongoing clinical development of IPI-549, Infinity's oral immuno-oncology development candidate that selectively inhibits ... |
|Infinity to Present at the 2017 BIO CEO & Investor Conference|
Feb 06, 2017
|CAMBRIDGE, Mass., Feb. 6, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the 2017 BIO CEO & Investor Conference in New York City on Monday, February 13, 2017. During the conference, Joseph Pearlberg, M.D., Ph.D., vice president, clinical development at Infinity will participate in a panel at 11:00 a.m. ET entitled, "CAR-T, TILs, and Bispecifics: Immuno-Oncology Challenges and Opportunities."
Additionally, Adelene Perkins, Infinity's chair and ... |